{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:16:08Z","timestamp":1772165768640,"version":"3.50.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15276-5","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T06:47:43Z","timestamp":1764398863000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multi-omics analysis reveals the role of tumor-infiltrating CD4+CCR7+ T cells in EGFR antibody resistance and prognosis of hepatocellular carcinoma"],"prefix":"10.1186","volume":"26","author":[{"given":"Zizhong","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lupeng","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guhe","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuoya","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yixin","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lai","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunchang","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,29]]},"reference":[{"issue":"Suppl","key":"15276_CR1","doi-asserted-by":"crossref","first-page":"S228","DOI":"10.3350\/cmh.2024.0824","volume":"31","author":"SY Hwang","year":"2025","unstructured":"Hwang SY, Danpanichkul P, Agopian V, Mehta N, Parikh ND, Abou-Alfa GK, et al. Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment. Clin Mol Hepatol. 2025;31(Suppl):S228-54.","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"15276_CR2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1136\/gutjnl-2024-333227","volume":"74","author":"P Danpanichkul","year":"2024","unstructured":"Danpanichkul P, Suparan K, Tothanarungroj P, Dejvajara D, Rakwong K, Pang Y, et al. Epidemiology of gastrointestinal cancers: a systematic analysis from the global burden of disease study 2021. Gut. 2024;74(1):26\u201334.","journal-title":"Gut"},{"issue":"10126","key":"15276_CR3","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus Sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163\u201373.","journal-title":"Lancet"},{"issue":"3","key":"15276_CR4","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s41591-024-02824-y","volume":"30","author":"HD Kim","year":"2024","unstructured":"Kim HD, Jung S, Lim HY, Ryoo BY, Ryu MH, Chuah S, et al. Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial. Nat Med. 2024;30(3):699\u2013707.","journal-title":"Nat Med"},{"issue":"6","key":"15276_CR5","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.21037\/tcr-24-837","volume":"13","author":"Z Qiang","year":"2024","unstructured":"Qiang Z, Wan J, Chen X, Wang H. Mechanisms and therapeutic targets of erbb family receptors in hepatocellular carcinoma: a narrative review. Transl Cancer Res. 2024;13(6):3156\u201378.","journal-title":"Transl Cancer Res"},{"issue":"3","key":"15276_CR6","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1053\/j.gastro.2021.06.008","volume":"161","author":"PK Haber","year":"2021","unstructured":"Haber PK, Puigveh\u00ed M, Castet F, Lourdusamy V, Montal R, Tabrizian P, et al. Evidence-based management of hepatocellular carcinoma: systematic review and meta-analysis of randomized controlled trials (2002\u20132020). Gastroenterology. 2021;161(3):879\u201398.","journal-title":"Gastroenterology"},{"key":"15276_CR7","doi-asserted-by":"crossref","DOI":"10.1186\/s13578-020-00407-1","volume":"10","author":"N Sueangoen","year":"2020","unstructured":"Sueangoen N, Tantiwetrueangdet A, Panvichian R. HCC-derived EGFR mutants are functioning, EGF-dependent, and erlotinib-resistant. Cell Biosci. 2020;10:41.","journal-title":"Cell Biosci"},{"issue":"14","key":"15276_CR8","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem E, K\u00f6hne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D\u2019Haens G, Pint\u00e9r T, Lim R, Bodoky G, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408\u201317.","journal-title":"N Engl J Med"},{"issue":"18","key":"15276_CR9","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1002\/cncr.32179","volume":"125","author":"VM Patil","year":"2019","unstructured":"Patil VM, Noronha V, Joshi A, Agarwal J, Ghosh-Laskar S, Budrukkar A, et al. A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer. Cancer. 2019;125(18):3184\u201397.","journal-title":"Cancer"},{"issue":"3","key":"15276_CR10","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/cncr.22829","volume":"110","author":"AX Zhu","year":"2007","unstructured":"Zhu AX, Stuart K, Blaszkowsky LS, Muzikansky A, Reitberg DP, Clark JW, et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer. 2007;110(3):581\u20139.","journal-title":"Cancer"},{"issue":"4","key":"15276_CR11","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-025-03993-6","volume":"74","author":"X Wang","year":"2025","unstructured":"Wang X, Li T, Slebos RJC, Chaudhary R, Guevara-Patino JA, Bonomi M, et al. Clinical significance of peripheral T-cell repertoire in head and neck squamous cell carcinoma treated with cetuximab and nivolumab. Cancer Immunol Immunother. 2025;74(4):142.","journal-title":"Cancer Immunol Immunother"},{"key":"15276_CR12","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.molimm.2021.07.008","volume":"137","author":"S Mahgoub","year":"2021","unstructured":"Mahgoub S, Abosalem H, Emara M, Kotb N, Maged A, Soror S. Restoring NK cells functionality via cytokine activation enhances cetuximab-mediated NK-cell ADCC: a promising therapeutic tool for HCC patients. Mol Immunol. 2021;137:221\u20137.","journal-title":"Mol Immunol"},{"issue":"4","key":"15276_CR13","first-page":"709","volume":"6","author":"H Zaryouh","year":"2023","unstructured":"Zaryouh H, De Pauw I, Baysal H, Melis J, Van den Bossche V, Hermans C, Lau HW, Lambrechts H, Merlin C, Corbet C, et al. Establishment of head and neck squamous cell carcinoma mouse models for cetuximab resistance and sensitivity. Cancer Drug Resist (Alhambra Calif). 2023;6(4):709\u201328.","journal-title":"Cancer Drug Resist (Alhambra Calif)"},{"key":"15276_CR14","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.2147\/IJGM.S312770","volume":"14","author":"Y Wang","year":"2021","unstructured":"Wang Y, Zhang M, Gong Y, Wu Q, Zhang L, Jiao S. Bioinformatic analysis of hepatocellular carcinoma cell lines to the efficacy of nimotuzumab. Int J Gen Med. 2021;14:2611\u201321.","journal-title":"Int J Gen Med"},{"key":"15276_CR15","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.86032","author":"X Wu","year":"2023","unstructured":"Wu X, Yan H, Qiu M, Qu X, Wang J, Xu S, et al. Comprehensive characterization of tumor microenvironment in colorectal cancer via molecular analysis. eLife. 2023. https:\/\/doi.org\/10.7554\/eLife.86032.","journal-title":"eLife"},{"issue":"3","key":"15276_CR16","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1158\/1078-0432.CCR-22-2355","volume":"29","author":"H Ge","year":"2023","unstructured":"Ge H, Ferris RL, Wang JH. Cetuximab responses in patients with HNSCC correlate to clonal expansion feature of peripheral and Tumor-Infiltrating T cells with top T-Cell receptor clonotypes. Clin Cancer Res. 2023;29(3):647\u201358.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"15276_CR17","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/hep.31766","volume":"74","author":"T Su","year":"2021","unstructured":"Su T, Huang M, Liao J, Lin S, Yu P, Yang J, et al. Insufficient radiofrequency ablation promotes hepatocellular carcinoma metastasis through N6-methyladenosine mRNA methylation-dependent mechanism. Hepatology. 2021;74(3):1339\u201356.","journal-title":"Hepatology"},{"issue":"11","key":"15276_CR18","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1158\/0008-5472.CAN-21-4425","volume":"83","author":"SR Boreddy","year":"2023","unstructured":"Boreddy SR, Nair R, Pandey PK, Kuriakose A, Marigowda SB, Dey C, et al. BCA101 is a tumor-targeted bifunctional fusion antibody that simultaneously inhibits EGFR and TGF\u03b2 signaling to durably suppress tumor growth. Cancer Res. 2023;83(11):1883\u2013904.","journal-title":"Cancer Res"},{"issue":"1","key":"15276_CR19","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.lungcan.2014.04.001","volume":"85","author":"A Pircher","year":"2014","unstructured":"Pircher A, Gamerith G, Amann A, Reinold S, Popper H, G\u00e4chter A, et al. Neoadjuvant chemo-immunotherapy modifies CD4+CD25+ regulatory T cells (Treg) in non-small cell lung cancer (NSCLC) patients. Lung Cancer. 2014;85(1):81\u20137.","journal-title":"Lung Cancer"},{"issue":"33","key":"15276_CR20","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.1200\/JCO.22.02630","volume":"41","author":"S Qin","year":"2023","unstructured":"Qin S, Li J, Bai Y, Wang Z, Chen Z, Xu R, et al. Nimotuzumab plus gemcitabine for K-Ras wild-type locally advanced or metastatic pancreatic cancer. J Clin Oncol. 2023;41(33):5163\u201373.","journal-title":"J Clin Oncol"},{"issue":"1","key":"15276_CR21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4161\/mabs.1.1.7509","volume":"1","author":"MS Ramakrishnan","year":"2009","unstructured":"Ramakrishnan MS, Eswaraiah A, Crombet T, Piedra P, Saurez G, Iyer H, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. mAbs. 2009;1(1):41\u20138.","journal-title":"mAbs"},{"issue":"39","key":"15276_CR22","volume":"96","author":"P Song","year":"2017","unstructured":"Song P, Yang J, Li X, Huang H, Guo X, Zhou G, et al. Hepatocellular carcinoma treated with anti-epidermal growth factor receptor antibody nimotuzumab: a case report. Medicine. 2017;96(39):e8122.","journal-title":"Medicine"},{"issue":"4","key":"15276_CR23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4161\/cbt.11.4.14097","volume":"11","author":"G Garrido","year":"2011","unstructured":"Garrido G, Tikhomirov IA, Rabasa A, Yang E, Gracia E, Iznaga N, et al. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer Biol Ther. 2011;11(4):373\u201382.","journal-title":"Cancer Biol Ther"},{"issue":"9","key":"15276_CR24","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1200\/JCO.2004.03.089","volume":"22","author":"T Crombet","year":"2004","unstructured":"Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol. 2004;22(9):1646\u201354.","journal-title":"J Clin Oncol"},{"issue":"11","key":"15276_CR25","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1016\/j.ymthe.2024.09.025","volume":"32","author":"WN Liu","year":"2024","unstructured":"Liu WN, Harden SL, Tan SLW, Tan RJR, Fong SY, Tan SY, et al. Single-cell RNA sequencing reveals anti-tumor potency of CD56(+) NK cells and CD8(+) T cells in humanized mice via PD-1 and TIGIT co-targeting. Mol Ther. 2024;32(11):3895\u2013914.","journal-title":"Mol Ther"},{"issue":"18","key":"15276_CR26","volume":"10","author":"Z Sun","year":"2024","unstructured":"Sun Z, Gao B, Song L, Wang B, Li J, Jiang H, et al. Single-cell RNA sequencing reveals intratumoral heterogeneity and multicellular community in primary hepatocellular carcinoma underlying microvascular invasion. Heliyon. 2024;10(18):e37233.","journal-title":"Heliyon"},{"issue":"1","key":"15276_CR27","volume":"13","author":"B Gao","year":"2023","unstructured":"Gao B, Wang Y, Lu S. Cellular senescence affects energy metabolism, immune infiltration and immunotherapeutic response in hepatocellular carcinoma. Sci Rep. 2023;13(1):1137.","journal-title":"Sci Rep"},{"issue":"1","key":"15276_CR28","volume":"38","author":"F Zhang","year":"2018","unstructured":"Zhang F, Wang W, Long Y, Liu H, Cheng J, Guo L, et al. Characterization of drug responses of mini patient-derived xenografts in mice for predicting cancer patient clinical therapeutic response. Cancer Commun. 2018;38(1):60.","journal-title":"Cancer Commun"},{"issue":"1","key":"15276_CR29","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jbiotec.2006.02.019","volume":"125","author":"W Neuhaus","year":"2006","unstructured":"Neuhaus W, Lauer R, Oelzant S, Fringeli UP, Ecker GF, Noe CR. A novel flow based hollow-fiber blood-brain barrier in vitro model with immortalised cell line PBMEC\/C1-2. J Biotechnol. 2006;125(1):127\u201341.","journal-title":"J Biotechnol"},{"issue":"4","key":"15276_CR30","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.cels.2019.03.003","volume":"8","author":"CS McGinnis","year":"2019","unstructured":"McGinnis CS, Murrow LM, Gartner ZJ. DoubletFinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors. Cell Syst. 2019;8(4):329-e337324.","journal-title":"Cell Syst"},{"issue":"6574","key":"15276_CR31","doi-asserted-by":"crossref","DOI":"10.1126\/science.abe6474","volume":"374","author":"L Zheng","year":"2021","unstructured":"Zheng L, Qin S, Si W, Wang A, Xing B, Gao R, et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells. Science. 2021;374(6574):abe6474.","journal-title":"Science"},{"issue":"6","key":"15276_CR32","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41591-023-02371-y","volume":"29","author":"Y Chu","year":"2023","unstructured":"Chu Y, Dai E, Li Y, Han G, Pei G, Ingram DR, et al. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance. Nat Med. 2023;29(6):1550\u201362.","journal-title":"Nat Med"},{"issue":"1","key":"15276_CR33","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.18009","volume":"28","author":"C Yang","year":"2024","unstructured":"Yang C, Cheng X, Gao S, Pan Q. Integrating bulk and single-cell data to predict the prognosis and identify the immune landscape in HNSCC. J Cell Mol Med. 2024;28(1):e18009.","journal-title":"J Cell Mol Med"},{"issue":"4","key":"15276_CR34","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1159\/000515305","volume":"10","author":"CL Hsu","year":"2021","unstructured":"Hsu CL, Ou DL, Bai LY, Chen CW, Lin L, Huang SF, et al. Exploring markers of exhausted CD8 T cells to predict response to immune checkpoint inhibitor therapy for hepatocellular carcinoma. Liver Cancer. 2021;10(4):346\u201359.","journal-title":"Liver Cancer"},{"issue":"18","key":"15276_CR35","doi-asserted-by":"crossref","first-page":"12525","DOI":"10.18632\/aging.206043","volume":"16","author":"J Ma","year":"2024","unstructured":"Ma J, Chen Z, Hou L. Revealing a cancer-associated fibroblast-based risk signature for pancreatic adenocarcinoma through single-cell and bulk RNA-seq analysis. Aging. 2024;16(18):12525\u201342.","journal-title":"Aging"},{"issue":"1","key":"15276_CR36","volume":"22","author":"H Jiang","year":"2024","unstructured":"Jiang H, Gao B, Meng Z, Wang Y, Jiao T, Li J, et al. Integrative multi-omics analysis reveals the role of tumor-associated endothelial cells and their signature in prognosis of intrahepatic cholangiocarcinoma. J Transl Med. 2024;22(1):948.","journal-title":"J Transl Med"},{"issue":"6","key":"15276_CR37","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/all.12408","volume":"69","author":"L Zhao","year":"2014","unstructured":"Zhao L, Yang W, Yang X, Lin Y, Lv J, Dou X, et al. Chemerin suppresses murine allergic asthma by inhibiting CCL2 production and subsequent airway recruitment of inflammatory dendritic cells. Allergy. 2014;69(6):763\u201374.","journal-title":"Allergy"},{"issue":"1","key":"15276_CR38","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.gastro.2021.09.018","volume":"162","author":"W Yang","year":"2022","unstructured":"Yang W, Liu H, Xu L, Yu T, Zhao X, Yao S, et al. GPR120 inhibits colitis through regulation of CD4(+) T cell interleukin 10 production. Gastroenterology. 2022;162(1):150\u201365.","journal-title":"Gastroenterology"},{"issue":"9","key":"15276_CR39","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1182\/bloodadvances.2016002360","volume":"1","author":"MD Lopez Robles","year":"2017","unstructured":"Lopez Robles MD, Pallier A, Huchet V, Le Texier L, Remy S, Braudeau C, et al. Cell-surface C-type lectin-like receptor CLEC-1 dampens dendritic cell activation and downstream Th17 responses. Blood Adv. 2017;1(9):557\u201368.","journal-title":"Blood Adv"},{"key":"15276_CR40","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.oraloncology.2018.05.013","volume":"82","author":"M Siano","year":"2018","unstructured":"Siano M, Espeli V, Mach N, Bossi P, Licitra L, Ghielmini M, et al. Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial. Oral Oncol. 2018;82:144\u201351.","journal-title":"Oral Oncol"},{"issue":"10","key":"15276_CR41","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1002\/ijc.33226","volume":"147","author":"AU Lindner","year":"2020","unstructured":"Lindner AU, Carberry S, Monsefi N, Barat A, Salvucci M, O\u2019Byrne R, Zanella ER, Cremona M, Hennessy BT, Bertotti A, et al. Systems analysis of protein signatures predicting cetuximab responses in KRAS, NRAS, BRAF and PIK3CA wild-type patient-derived xenograft models of metastatic colorectal cancer. Int J Cancer. 2020;147(10):2891\u2013901.","journal-title":"Int J Cancer"},{"issue":"6","key":"15276_CR42","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/gutjnl-2018-316408","volume":"68","author":"R Pinyol","year":"2019","unstructured":"Pinyol R, Montal R, Bassaganyas L, Sia D, Takayama T, Chau GY, et al. Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. Gut. 2019;68(6):1065\u201375.","journal-title":"Gut"},{"issue":"1","key":"15276_CR43","doi-asserted-by":"crossref","DOI":"10.1038\/s43856-024-00728-z","volume":"5","author":"A Yazdani","year":"2025","unstructured":"Yazdani A, Lenz HJ, Pillonetto G, Mendez-Giraldez R, Yazdani A, Sanoff H, et al. Gene signatures derived from transcriptomic-causal networks stratify colorectal cancer patients for effective targeted therapy. Commun Med. 2025;5(1):9.","journal-title":"Commun Med"},{"issue":"12","key":"15276_CR44","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1002\/cncr.23489","volume":"112","author":"A Asnacios","year":"2008","unstructured":"Asnacios A, Fartoux L, Romano O, Tesmoingt C, Louafi SS, Mansoubakht T, Artru P, Poynard T, Rosmorduc O, Hebbar M, et al. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer. 2008;112(12):2733\u20139.","journal-title":"Cancer"},{"issue":"1","key":"15276_CR45","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1158\/1078-0432.CCR-05-1855","volume":"12","author":"U Reusch","year":"2006","unstructured":"Reusch U, Sundaram M, Davol PA, Olson SD, Davis JB, Demel K, et al. Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model. Clin Cancer Res. 2006;12(1):183\u201390.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"15276_CR46","doi-asserted-by":"crossref","first-page":"377","DOI":"10.7785\/tcrt.2012.500389","volume":"13","author":"J Geng","year":"2014","unstructured":"Geng J, Li X, Lang X, Qiao C, Hu M, Yang J, et al. Combination of cetuximab and rapamycin enhances the therapeutic efficacy in hepatocellular carcinoma. Technol Cancer Res Treat. 2014;13(4):377\u201385.","journal-title":"Technol Cancer Res Treat"},{"issue":"11","key":"15276_CR47","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.bcp.2005.09.007","volume":"70","author":"A Huether","year":"2005","unstructured":"Huether A, H\u00f6pfner M, Baradari V, Schuppan D, Scher\u00fcbl H. EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem Pharmacol. 2005;70(11):1568\u201378.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"15276_CR48","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/bcp.14937","volume":"88","author":"D Vera-Yunca","year":"2022","unstructured":"Vera-Yunca D, Parra-Guillen ZP, Girard P, Troc\u00f3niz IF, Terranova N. Relevance of primary lesion location, tumour heterogeneity and genetic mutation demonstrated through tumour growth inhibition and overall survival modelling in metastatic colorectal cancer. Br J Clin Pharmacol. 2022;88(1):166\u201377.","journal-title":"Br J Clin Pharmacol"},{"key":"15276_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241612538","author":"RJ Turner","year":"2023","unstructured":"Turner RJ, Guy TV, Geraghty NJ, Splitt A, Watson D, Brungs D, et al. Low Pretreatment CD4+:CD8+ T Cell Ratios and CD39+CD73+CD19+ B Cell Proportions Are Associated with Improved Relapse-Free Survival in Head and Neck Squamous Cell Carcinoma. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms241612538.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"15276_CR50","volume":"11","author":"Y Cheng","year":"2021","unstructured":"Cheng Y, Borcherding N, Ogunsakin A, Lemke-Miltner CD, Gibson-Corley KN, Rajan A, et al. The anti-tumor effects of cetuximab in combination with VTX-2337 are T cell dependent. Sci Rep. 2021;11(1):1535.","journal-title":"Sci Rep"},{"key":"15276_CR51","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jare.2022.04.010","volume":"44","author":"L Huang","year":"2023","unstructured":"Huang L, Zhang X, Fan J, Liu X, Luo S, Cao D, et al. EGFR promotes the apoptosis of CD4(+) T lymphocytes through TBK1\/Glut1 induced Warburg effect in sepsis. J Adv Res. 2023;44:39\u201351.","journal-title":"J Adv Res"},{"issue":"1","key":"15276_CR52","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-023-02691-4","volume":"42","author":"K Okuyama","year":"2023","unstructured":"Okuyama K, Naruse T, Yanamoto S. Tumor microenvironmental modification by the current target therapy for head and neck squamous cell carcinoma. J Exp Clin Cancer Res. 2023;42(1):114.","journal-title":"J Exp Clin Cancer Res"},{"issue":"8","key":"15276_CR53","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/ijc.33446","volume":"148","author":"A von Witzleben","year":"2021","unstructured":"von Witzleben A, Fehn A, Grages A, Ezi\u0107 J, Jeske SS, Puntigam LK, et al. Prospective longitudinal study of immune checkpoint molecule (ICM) expression in immune cell subsets during curative conventional therapy of head and neck squamous cell carcinoma (HNSCC). Int J Cancer. 2021;148(8):2023\u201335.","journal-title":"Int J Cancer"},{"key":"15276_CR54","volume":"2022","author":"D Chen","year":"2022","unstructured":"Chen D, Li X, Li H, Wang K, Tian X. Identification of immune-related prognostic mRNA and LncRNA in patients with hepatocellular carcinoma. J Oncol. 2022;2022:5313149.","journal-title":"J Oncol"},{"issue":"1","key":"15276_CR55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13402-017-0352-6","volume":"41","author":"Y Vahidi","year":"2018","unstructured":"Vahidi Y, Faghih Z, Talei AR, Doroudchi M, Ghaderi A. Memory CD4(+) T cell subsets in tumor draining lymph nodes of breast cancer patients: a focus on T stem cell memory cells. Cell Oncol. 2018;41(1):1\u201311.","journal-title":"Cell Oncol"},{"issue":"1","key":"15276_CR56","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13046-021-02215-y","volume":"41","author":"T Flieswasser","year":"2022","unstructured":"Flieswasser T, Van den Eynde A, Van Audenaerde J, De Waele J, Lardon F, Riether C, de Haard H, Smits E, Pauwels P, Jacobs J. The CD70-CD27 axis in oncology: the new kids on the block. J Experimental Clin Cancer Res. 2022;41(1):12.","journal-title":"J Experimental Clin Cancer Res"},{"issue":"12","key":"15276_CR57","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/cvr\/cvae133","volume":"120","author":"J Yu","year":"2024","unstructured":"Yu J, Long B, Li Z, Tian X, Li D, Long J, et al. Central memory CD4\u2009+\u2009T cells play a protective role against immune checkpoint inhibitor-associated myocarditis. Cardiovasc Res. 2024;120(12):1442\u201355.","journal-title":"Cardiovasc Res"},{"key":"15276_CR58","volume":"15","author":"H Wang","year":"2024","unstructured":"Wang H, Huang H, Liu T, Chen Y, Li J, He M, et al. Peripheral blood lymphocyte subsets predict the efficacy of TACE with or without PD-1 inhibitors in patients with hepatocellular carcinoma: a prospective clinical study. Front Immunol. 2024;15:1325330.","journal-title":"Front Immunol"},{"key":"15276_CR59","volume":"14","author":"LN Zhang","year":"2024","unstructured":"Zhang LN, Chen JY, Liu YX, Zhang Y, Hong LL, Li XX, et al. Identification of LncRNA dual targeting PD-L1 and PD-L2 as a novel prognostic predictor for gastric cancer. Front Oncol. 2024;14:1341056.","journal-title":"Front Oncol"},{"key":"15276_CR60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115252","volume":"217","author":"S Rosnev","year":"2025","unstructured":"Rosnev S, Sterner B, Schiele P, Kolling S, Martin M, Fl\u00f6rcken A, et al. Reduced monocytic IL10 expression in PD1 inhibitor-treated patients is a harbinger of severe immune-related adverse events. Eur J Cancer. 2025;217:115252.","journal-title":"Eur J Cancer"},{"key":"15276_CR61","volume":"10","author":"D Ain","year":"2021","unstructured":"Ain D, Shaikh T, Manimala S, Ghebrehiwet B. The role of complement in the tumor microenvironment. Fac Rev. 2021;10:80.","journal-title":"Fac Rev"},{"issue":"1","key":"15276_CR62","volume":"10","author":"J Qin","year":"2025","unstructured":"Qin J, Gong Q, Zhou C, Xu J, Cheng Y, Xu W, et al. Differential expression pattern of CC chemokine receptor 7 guides precision treatment of hepatocellular carcinoma. Signal Transduct Target Ther. 2025;10(1):229.","journal-title":"Signal Transduct Target Ther"},{"issue":"10","key":"15276_CR63","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1111\/cas.15498","volume":"113","author":"H Han","year":"2022","unstructured":"Han H, Zhu W, Lin T, Liu C, Zhai H. N4BP3 promotes angiogenesis in hepatocellular carcinoma by binding with KAT2B. Cancer Sci. 2022;113(10):3390\u2013404.","journal-title":"Cancer Sci"},{"issue":"1","key":"15276_CR64","volume":"24","author":"A Zuo","year":"2024","unstructured":"Zuo A, Lv J, Jia W, Ba Y, Liu S, Zhang Y, et al. High ratio of resident to exhausted CD4\u2009+\u2009T cells predicts favorable prognosis and potentially better immunotherapeutic efficacy in hepatocellular carcinoma. BMC Cancer. 2024;24(1):1152.","journal-title":"BMC Cancer"},{"issue":"5","key":"15276_CR65","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1097\/XCS.0000000000000638","volume":"236","author":"HF Ding","year":"2023","unstructured":"Ding HF, Yang T, Lv Y, Zhang XF, Pawlik TM. Development and validation of an \u03b1-fetoprotein tumor burden score model to predict postrecurrence survival among patients with hepatocellular carcinoma. J Am Coll Surg. 2023;236(5):982\u201392.","journal-title":"J Am Coll Surg"},{"issue":"12","key":"15276_CR66","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1007\/s10620-020-06797-z","volume":"66","author":"K Lin","year":"2021","unstructured":"Lin K, Huang Q, Zeng J, Ding Z, Wang L, Chen Z, et al. Clinical significance of alpha-fetoprotein in alpha-fetoprotein negative hepatocellular carcinoma underwent curative resection. Dig Dis Sci. 2021;66(12):4545\u201356.","journal-title":"Dig Dis Sci"},{"issue":"15","key":"15276_CR67","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.23.02745","volume":"42","author":"JD Gordan","year":"2024","unstructured":"Gordan JD, Kennedy EB, Abou-Alfa GK, Beal E, Finn RS, Gade TP, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update. J Clin Oncol. 2024;42(15):1830\u201350.","journal-title":"J Clin Oncol"},{"issue":"14","key":"15276_CR68","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1200\/JCO.18.01798","volume":"37","author":"F Innocenti","year":"2019","unstructured":"Innocenti F, Ou FS, Qu X, Zemla TJ, Niedzwiecki D, Tam R, et al. Mutational analysis of patients with colorectal cancer in CALGB\/SWOG 80405 identifies new roles of microsatellite instability and tumor mutational burden for patient outcome. J Clin Oncol. 2019;37(14):1217\u201327.","journal-title":"J Clin Oncol"},{"issue":"10","key":"15276_CR69","doi-asserted-by":"crossref","first-page":"14006","DOI":"10.1096\/fj.201902910RRR","volume":"34","author":"CS Zhan","year":"2020","unstructured":"Zhan CS, Chen J, Chen J, Zhang LG, Liu Y, Du HX, et al. CaMK4\u2010dependent phosphorylation of Akt\/mTOR underlies Th17 excessive activation in experimental autoimmune prostatitis. FASEB J. 2020;34(10):14006\u201323.","journal-title":"FASEB J"},{"key":"15276_CR70","volume":"13","author":"G Sun","year":"2022","unstructured":"Sun G, Zheng W, Tan P, Zhou J, Tang W, Cao H, et al. Comprehensive analysis of VCAN expression profiles and prognostic values in HCC. Front Genet. 2022;13:900306.","journal-title":"Front Genet"},{"issue":"1","key":"15276_CR71","volume":"29","author":"YC Wen","year":"2024","unstructured":"Wen YC, Lin YW, Ho KH, Yang YC, Lai FR, Chu CY, et al. The oncogenic ADAMTS1-VCAN-EGFR cyclic axis drives anoikis resistance and invasion in renal cell carcinoma. Cell Mol Biol Lett. 2024;29(1):126.","journal-title":"Cell Mol Biol Lett"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15276-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15276-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15276-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T06:02:41Z","timestamp":1767679361000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-025-15276-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,29]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15276"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15276-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7189781\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,29]]},"assertion":[{"value":"22 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study complies with the Helsinki Declaration. All participants provided written informed consent prior to enrollment. All animal experiments comply with the ARRIVE guidelines. Animals were purchased from Charles River Laboratories with informed consent and maintained under standard laboratory conditions. Mice were euthanized by cervical dislocation while under deep anesthesia after experiment. Both the clinical study and animal experiments protocol received approval from the Ethics Committee of PLA General Hospital (approval number S2022-313-02, dated July 27, 2022.).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}